Fitch cuts Hapvida's rating to A(bra) with negative outlook

Fitch Ratings cut the national credit rating of Brazilian healthcare operator Hapvida from AA+(bra) to A(bra) and shifted its rating outlook from stable to negative on October 9, 2026. Analysts Tatiana Thomaz, Natalia Brandao, and Andre Correa stated that the downgrade reflects the persistent deterioration of Hapvida's operational and financial profile.

The agency pointed to recurrent cash burn, net subscriber losses, rising judicial litigation expenses, and elevated medical loss ratios. Frustration in capturing operational synergies and remaining complexities from past mergers and acquisitions have blocked expected efficiency gains, delaying margin recovery. Fitch also highlighted rising competition, especially in Brazil's Southeast, regulatory fines, and mismatches between plan pricing and medical care costs.

Fitch projects that operating cash flow will stay negative over the next two fiscal years, forecasting a deficit of BRL 280 million in 2026 and BRL 45 million in 2027. Analysts expect leverage to remain between 3.5 and 4.0 times through the end of 2027, warning that Hapvida's leeway to service obligations could rapidly deplete without an operational rebound.